Evidence map›Paper›PMID 36556046›Full record

ArticleJournal of clinical medicine2022

Immunohistochemical Algorithm for the Classification of Muscle-Invasive Urinary Bladder Carcinoma with Lymph Node Metastasis: An Institutional Study.

Karla Beatríz Peña, Francesc Riu, Josep Gumà, Francisca Martínez-Madueño, Maria José Miranda, Anna Vidal, Marc Grifoll, Joan Badia, Marta Rodriguez-Balada, David Parada

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Karla Beatríz PeñaMolecular Pathology Unit, Department of Pathology, Hospital Universitari de Sant Joan, 43204 Reus, Spain.
Francesc RiuMolecular Pathology Unit, Department of Pathology, Hospital Universitari de Sant Joan, 43204 Reus, Spain.
Josep GumàInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.ORCID 0000-0001-7541-9832
Francisca Martínez-MadueñoInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.
Maria José MirandaInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.
Anna VidalInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.
Marc GrifollInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.ORCID 0000-0002-1948-328X
Joan BadiaInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.ORCID 0000-0001-7446-7365
Marta Rodriguez-BaladaInstitut d'Investigació Sanitària Pere Virgili, 43204 Reus, Spain.ORCID 0000-0002-2691-8819
David ParadaMolecular Pathology Unit, Department of Pathology, Hospital Universitari de Sant Joan, 43204 Reus, Spain.ORCID 0000-0002-8894-2312

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Muscle-invasive urothelial carcinoma represents 20% of newly diagnosed cases of bladder cancer, and most cases show aggressive biological behavior with a poor prognosis. It is necessary to identify biomarkers that can be used as prognostic and predictive factors in daily clinical practice. In our study, we analyzed different antibodies in selected cases of muscle-invasive urinary bladder carcinoma and lymph node metastasis to identify immunohistochemical types and their value as possible prognostic factors. A total of 38 patients were included, 87% men and 13% women, with a mean age of 67.8 years. The most frequent histopathological type was urothelial carcinoma. In the primary lesion, the mixed type was the most common. In unilateral metastasis, the mixed type was the most frequently found. In cases of primary lesions and bilateral metastasis, the luminal and mixed types were observed. The luminal subtype was the most stable in immunohistochemical expression across primary tumors and metastases. The basal type showed a better prognosis in terms of disease-free survival. In conclusion, immunohistochemical studies are useful in assessing primary and metastatic lesions in patients with urothelial carcinoma. Immunohistochemical classification can typify muscle-invasive urothelial carcinoma, and the immunophenotype seems to have prognostic implications.

Indexed as

bladdercancerclassificationheterogeneityimmunohistochemicallymph nodemetastasesmuscle invasiveprognosis

Identifiers

PMID36556046
PMCPMC9788404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.